EPO (erythropoietin) is an endogenous hormone that regulates red blood cell production and serves as a critical biomarker and therapeutic target in lower-risk Myelodysplastic Syndromes (MDS).
For your BCOP studies, keep these pharmacist-critical points in mind:
- Predictive Biomarker: A baseline serum EPO level < 500 units/L is the strongest predictor of a positive response to erythropoiesis-stimulating agents (ESAs).
- Therapeutic Agents: Pharmacological versions (ESAs) include epoetin alfa, its biosimilar epoetin alfa-epbx, and darbepoetin.
- MDS-Specific Dosing: Required doses are significantly higher than those for other types of anemia, typically starting at 300 units/kg SQ three times weekly.
- Clinical Goal: The objective is to reduce red blood cell transfusion needs, titrating to a target hemoglobin of 10–12 g/dL.
- Safety Note: Unlike in some solid tumors, ESAs in MDS have not been shown to hasten progression to AML or decrease overall survival.
If a patient’s EPO level is > 500 units/L, they are unlikely to respond to epoetin, and agents like luspatercept are typically preferred if ring sideroblasts are present.
Synonyms
EPO